- Home
- CIFR vs RYTM Comparison
CIFR vs RYTM Comparison
Compare CIFR & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CIFR | RYTM |
|---|---|---|
| Founded | 2021 | 2008 |
| Country | United States | United States |
| Employees | 66 | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7B | 5.8B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | CIFR | RYTM |
|---|---|---|
| Price | $17.12 | $82.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 14 |
| Target Price | $24.91 | ★ $131.14 |
| AVG Volume (30 Days) | ★ 21.6M | 505.0K |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.34 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.29 | $55.34 |
| Revenue Next Year | $240.53 | $86.06 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.88 | $55.31 |
| 52 Week High | $25.52 | $122.20 |
Technical Indicators
Market Signals| Indicator | CIFR | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 51.46 | 39.88 |
| Support Level | $12.53 | $74.50 |
| Resistance Level | $17.26 | $90.79 |
| Average True Range (ATR) | 1.37 | 3.24 |
| MACD | -0.17 | -0.28 |
| Stochastic Oscillator | 17.82 | 23.60 |
Price Performance
Historical ComparisonAbout CIFR Cipher Mining Inc.
Cipher Digital Inc is focused on high-performance computing (HPC) data center development and operations. It is engaged in developing and operating data centers designed for HPC workloads. Its operations include managing power assets and capital allocation in response to market conditions and demand for AI-related computing capacity.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.